1	Comparison of mechanical homogenization versus enzymatic digestion sample preparation
2	methodologies for SARS-CoV-2 detection in saliva for surveillance of variants of concern
3	on the University of Tennessee campus in early 2021.
4	(Short Title: Comparison of three detection methods for SARS-CoV-2 variants from saliva)
5	Magen R. Poindexter <sup>1</sup> , Tingting Xu <sup>1</sup> , Cynthia M. Swift <sup>1,5</sup> , Caleb M Proctor <sup>6</sup> , Fadime Kara-
6	Murdoch <sup>1,5,10</sup> , Zachary P Morehouse <sup>6,7,8</sup> , Gabriella L Ryan <sup>6</sup> , Frank E. Löffler <sup>1,2,3,4,5</sup> , Rodney J
7	Nash <sup>6,8,9,*</sup>
8	Affiliations:
9	1. Center for Environmental Biotechnology, University of Tennessee, Knoxville, TN,
10	United States
11	2. Department of Microbiology, University of Tennessee, Knoxville, TN, United States
12	3. Department of Civil and Environmental Engineering, University of Tennessee,
13	Knoxville, TN, United States
14	4. Department of Biosystems Engineering and Soil Science, University of Tennessee,
15	Knoxville, TN, United States
16	5. Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN, United States
17	6. Omni International Inc, A PerkinElmer Company, Kennesaw, GA, United States
18	7. Michigan State University College of Osteopathic Medicine, East Lansing, MI, United
19	States
20	8. Jeevan BioSciences, Tucker, GA, United States
21	9. Department of Biology, Georgia State University, Atlanta, GA, United States
22	10. Battelle Memorial Institute, Columbus, OH, United States

23 \* Corresponding author, Rodney Nash, <u>rnash@omni-inc.com</u>

- 25 Notice: This manuscript has been authored by UT-Battelle, LLC, under contract DE-AC05-
- 26 00OR22725 with the US Department of Energy (DOE). The US government retains, and the
- 27 publisher, by accepting the article for publication, acknowledges that the US government retains
- a nonexclusive, paid-up, irrevocable, worldwide license to publish or reproduce the published
- 29 form of this manuscript, or allow others to do so, for US government purposes. DOE will
- 30 provide public access to these results of federally sponsored research in accordance with the
- 31 DOE Public Access Plan (<u>http://energy.gov/downloads/doe-public-access-plan</u>).

# 33 Abstract:

34	The SARS-CoV-2 pandemic has profoundly impacted communities across the globe, requiring
35	accurate and accessible diagnostic technologies in support of public health mitigation efforts. As
36	testing has evolved throughout the course of the pandemic, varying sample preparation
37	methodologies have been employed. Herein we perform a comparison of three commercial
38	sample preparation methods: two mechanical homogenization workflows and one enzymatic
39	digestion approach for the detection of SARS-CoV-2 from biomarker genes in 20 human saliva
40	pools. SARS-CoV-2 variants of concern were also identified on the University of Tennessee,
41	Knoxville campus during the spring semester of 2021 utilizing the commercial PerkinElmer
42	PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit. Two hundred and ten (210) human
43	saliva pools were selected and analyzed for the presence of SARS-CoV-2 variants of concern
44	providing insight into the utility of these various commercial workflows for integration into
45	current public health SARS-CoV-2 surveillance measures.
46	Keywords:

47 SARS-CoV-2, variant of concern, diagnostics, sample preparation

## 49 **Introduction:**

Accurate and accessible diagnostic testing provides the cornerstone of most public health and 50 51 treatment efforts for viral disease. The global pandemic caused by SARS-CoV-2 infections 52 required rapid advancement in diagnostic techniques and technologies to maintain pace with the global demand for accurate viral testing [1]. Throughout the pandemic, quantitative polymerase 53 54 chain reaction (qPCR) based diagnostic assays have been the gold standard for SARS-CoV-2 55 diagnostics [1]. In March 2020, ThermoFisher Scientific commercialized one of the first diagnostics assays for the detection of SARS-CoV-2; a TaqPath COVID-19 qPCR based kit 56 57 which relies on fluorescence technologies allowing for multiplexing of PCR assays to detect and 58 distinguish between different gene targets in the same sample. The TaqPath COVID-19 qPCR 59 kit was granted emergency use for clinical testing by the FDA on March 13, 2020 60 (https://www.fda.gov/media/136113/download). The qPCR based assays developed for SARS-CoV-2 diagnostics have experienced multiple iterations of refinement, evolving from the initial 61 62 nasopharyngeal swab tests to assays for other sample materials including saliva, wastewater, and feces [2-6]. This rapid diversification of sample inputs for qPCR detection of SARS-CoV-2 63 biomarkers was driven by a necessity to maintain public compliance with testing efforts while 64 maintaining accuracy and availability of testing. 65 As the pandemic progressed, multiple variants of concern emerged across the globe with the 66

potential to evade current diagnostic assays and available treatments [7]. It soon became a priority of many health organizations to identify and track these emerging variants of concern across different geographic areas and populations [8]. Diagnostic assay development became an increasing priority to allow for SARS-CoV-2 variants of concern detection to support public health efforts.

In this study, we compare three qPCR based methodologies for SARS-CoV-2 diagnostics using 72 human saliva samples collected on the University of Tennessee, Knoxville campus. Two of these 73 74 methodologies, the SalivaDirect with Proteinase K and the KingFisher RNA Extraction method, 75 are commercially available and were compared to the Omni Direct-to-PCR (dPCR) method [9-76 11]. This comparative evaluation provides insight into the ability of different workflows to 77 accurately detect viral RNA within saliva samples. While less invasive for the patient to provide, 78 these samples often have increased PCR inhibitors present, making saliva a more difficult sample 79 to process and achieve sensitive detection of SARS-CoV-2 biomarker genes. Thus, comparative studies assessing the impact of sample preparation workflows are crucial for establishing 80 confidence in diagnostic testing with this sample medium. 81 82 Additionally, the human saliva samples collected for this study were screened for variants of 83 concern utilizing the commercial PerkinElmer PKamp VariantDetect SARS-CoV-2 RT-PCR 84 Assay kit. These samples were collected throughout the 2021 spring semester, and demonstrated 85 the ability of this kit to accurately detect and differentiate between variants of SARS-CoV-2 as

they spread throughout the campus community.

#### 87 Materials and Methods:

This study assessed the efficacy of the Omni protocol for detection of SARS-CoV-2 RNA in deidentified human saliva samples. The performance of the Omni Direct-to-PCR (dPCR) approach was compared against a standard RNA extraction method (i.e., KingFisher extraction) commonly used in Clinical Laboratory Improvement Amendments (CLIA) certified labs as well as the SalivaDirect protocol developed by the Yale School of Public Health, New Haven, CT [12]. The Omni dPCR method utilizes samples homogenized by the Bead Ruptor Elite (Omni, Cat. No. 19-042E) and then added directly to the qPCR reactions. The KingFisher extraction protocol

relies upon viral particle lysis and mechanical disruption of the virus. The SalivaDirect protocol
combines both Proteinase K and heat treatment to denature human saliva samples.

97 The samples utilized in this study were obtained from the University of Tennessee, Knoxville

98 campus in the Spring 2021 semester. All participants were consented via written and oral consent

99 prior to providing saliva samples. Saliva samples provided for the research in this study were

100 deidentified prior to being handed over to the lab for further use. All research was approved

under protocol IBC-20-547-2 approved on July 6 2020 by the UTK institutional review board.

102 In early summer 2020, the University of Tennessee, Knoxville campus developed and validated

103 protocols to detect SARS-CoV-2 for public health surveillance using RT-qPCR assays that target

the viral envelope (E), nucleocapsid (N), RNA polymerase (RdRP), and human Ribonuclease P

105 (RNase P, used as a positive control) genes for human saliva under IBC-20-547-2 (IBC-20-547-

106 2; July 6, 2020). The E gene provides for the outermost layer of the virus protecting the genetic

107 material when traveling from one host to another. The N gene provides the protective coat of

108 proteins associating with the viral nucleic acids. The RdRP gene is one of 16 nonstructural

109 proteins that are produced in the overlapping open reading frames (ORF1ab region) that encode

110 for polyproteins PP1ab and PP1a. The function of these nonstructural proteins includes viral

111 transcription, replication, proteolytic processing, suppression of host immunity and host gene

expression [13]. The E, N, and RdRP/ORF1abregions have been the commonly analyzed viraltargets for diagnosis.

The de-identified human saliva samples used in this study were chosen based upon previous
testing using the protocols established by the University of Tennessee SARS-CoV-2 Surveillance
Testing Laboratory to include known SARS-CoV-2 positive and known SARS-CoV-2 negative
human saliva samples. Table 1 below shows the published primer and probe sets specifically

targeting the E, RdRP, and RNase P genes that were used in this study [3, 4, 6]. Although the

viral N gene was originally included in the multiplexed qPCR assays during previous testing, it is

excluded in this study as both the E and RdRP targets are sufficient for detecting the presence of

121 the viral genome in the saliva samples.

122

Primer or Probe	Primer Sequence (5'-3')	Target	Reference	
E_Sarbeco_F1	ACAGGTACGTTAATAGTTAATAGCGT		[4]	
E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA	SARS-CoV-2 envelope (E)	[4]	
E_Sarbeco_P1	VIC-ACACTAGCCATCCTTACTGCGCTTCG-QSY		[4]	
		SARS-CoV-2 RNA	[6]	
KUKP_FIlew	0104441001041010100000	polymerase (RdRP)	[0]	
RdRP_Rnew	CAAATGTTAAAAACACTATTAGCATA	AGCATA DNIA L (DIDD)		
RdRP_SARSr-P2	FAM-CAGGTGGAACCTCATCAGGAGATGC-QSY	KNA polymerase (RdKP)	[6]	
DNasa D E		Human Ribonuclease P	[2]	
Kinase P-r	AGATTIGGACCIOCOAOCO	(RNase P)	[3]	
RNase P-R	GAGCGGCTGTCTCCACAAGT	Dihamalaan D(DNaan D)	[3]	
RNase P-P	JUN-TTCTGACCTGAAGGCTCTGCGCG-QSY	Ribonuciease P (Rivase P)	[3]	

**Table 1.** Primers and probes used in this study.

124

Omni provided a PerkinElmer PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit
(PerkinElmer, Cat. No. 4224-0010) to detect and differentiate SARS-CoV-2 variants. The

127 PerkinElmer kit uses different combinations of multiplexed primers and TaqMan probes to detect

different SARS-CoV-2 variants (i.e., combination C detects wildtype, Alpha, Beta and Gamma

variants and combination F detects Delta and Kappa variants). To demonstrate the utility of this

130 kit, 210 de-identified human saliva pools were used to test the validity and efficacy of this kit.

131 To verify that assay reagents performed according to expectations, the controls used included an

132 extraction control with nuclease free water added instead of a human saliva sample; a no

- template PCR control with nuclease-free water added instead of RNA during RT-qPCR; and a
- 134 positive control of 5  $\mu$ L of 1.05x10<sup>3</sup> genome copy equivalents/ $\mu$ L of RNA from inactivated

135 SARS-CoV-2 (USA-WA1/2020) was added during RT-qPCR (BEI Resources, Cat. No. NR-

- 136 52286). The PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit detects 4 different SARS-
- 137 CoV-2 mutations which include the Alpha variant (B1.1.7 United Kingdom, September 2020),
- the Beta variant (B.1.351 South Africa, May 2020), Gama variant (P.1 Brazil, November
- 139 2020), Delta variant (B.1.617 India, October 2020), and the Kappa variant (B.1.617.1 India,
- 140 April 2021) (Table 3).
- 141

142 **Experiment 1: Comparison of Sample Processing Method:** Twenty saliva pools each

- 143 consisting of five individual human saliva samples were selected including 18 known positive
- 144 (+) saliva pools; and 2 known negative (-) saliva pools. TaqPath<sup>TM</sup> 1-Step Multiplex Master Mix
- 145 (No ROX) (ThermoFisher Cat. No. A28523; Waltham, MA) was added to multiplex assays
- 146 (Table 2) for the detection of the E gene, the RdRP gene, and the RNase P gene, the latter
- serving as an internal amplification control gene. Extraction negative controls were established
- 148 by adding sterile water in the place of a saliva pool. RT-qPCR negative controls (no template
- 149 control) consisted of complete assays with 5  $\mu$ L of nuclease-free water replacing the RNA
- template. Positive controls for the E and RdRP genes were established by adding  $5 \,\mu$ L of
- 151  $1.05 \times 10^3$  genome equivalents/µL synthetic RNA to give a concentration of  $5.25 \times 10^3$  genome
- 152 copy equivalents per reaction (BEI Resources, Cat. No. NR-52286).

<b>Reaction Components</b>	Stock conc. (µM)	Final Conc. (	153 nM)
Nuclease-free water			154
E_Sarbeco_P1	100	250	155
E_Sarbeco_F1	100	600	155
E_Sarbeco_R2	100	600	156
RdRP_SARSr-P2	100	250	453
RdRP_Fnew	100	600	157
RdRP_Rnew	100	600	158
RNase P-P	100	250	
RNase P-F	100	600	159
RNase P-R	100	600	160
TaqPath 1-Step Multiplex Master Mix (No			100
ROX)	4X	1X	161
AmpliTaq	5 U/uL	1 U/rxn	
			162

- 163 **Table 2.** RT-qPCR reaction multiplex assay mixture used for each of the three processing
- 164 methods with the only change being the source of the template.

165	1)	<u>Omni Direct-to-PCR method:</u> Each human saliva pool (500 $\mu$ L) was transferred to a 2-
166		mL Omni bead tube (Omni, Cat. No. 19-628). The bead tubes were placed inside the
167		Bead Ruptor Elite (Omni, Cat. No. 19-042E) and agitated at 4.5 m/s for 30 seconds. Five
168		$\mu$ L of each processed pool were used for qPCR.
169	2)	KingFisher extraction method: The MagMAX <sup>TM</sup> -96 Viral RNA Isolation Kit and kit
170		supplied buffers were used for this extraction method following manufacturer protocol
171		(ThermoFisher, Cat. No. AM1836; Waltham, MA) with the addition of Dithiothreitol
172		(DTT) to lower the viscosity of the saliva. DTT (Sigma-Aldrich, Cat. No. 501656980,
173		Inc., St. Louis, MO) (20 $\mu L$ of a 50 mM aqueous stock solution) was added to 200 $\mu L$ of
174		each human saliva pool and incubated at room temperature for 30 minutes. After the
175		incubation, Proteinase K (5 $\mu$ L of a 1-5% aqueous stock solution; ThermoFisher Cat. No.
176		A42363; Waltham, MA) and 275 $\mu$ L binding buffer/bead mix (provided in kit) were
177		added to each sample. The RNA was first washed with wash buffer (provided in kit) and
178		then with 80% molecular grade ethanol, before RNA was eluted in 50 $\mu$ L elution buffer
179		(provided by in kit). Five $\mu L$ of the RNA extract from each sample were used for qPCR
180	3)	RNA extraction following SalivaDirect with Proteinase K treatment: Proteinase K (2.5
181		$\mu$ L of a 1-5% aqueous stock solution; ThermoFisher Cat. No. A42363; Waltham, MA)
182		was added to 50 $\mu$ L of human saliva pool and vortexed for 1 minute. Samples were then
183		heated to 95°C in the Veriti <sup>™</sup> 96-well Thermal Cycler (Applied Biosystems, Model No.
184		9902, Waltham, MA) for 5 minutes. Five $\mu$ L from each sample were used for qPCR [12].
185		
186	Exper	iment 2: Variant tracking: A total of 210 positive human saliva pools collected from
187	Septer	nber 2020 through April 2021 were subjected to variant testing with the PKamp

188	VariantDetect SARS-CoV-2 RT-PCR Assay kit. These 210 positive human saliva pools were
189	selected based upon previous identification using the multiplex qPCR assay protocol established
190	by the University of Tennessee SARS-CoV-2 Surveillance Testing Laboratory. RNA was freshly
191	extracted from each of the 210 positive human saliva pools using the KingFisher Flex
192	MagMAX <sup>TM</sup> -96 Viral RNA Isolation Kit per manufacturer protocol (ThermoFisher, Cat No.
193	AM1836; Waltham, MA) with the addition of DTT. Immediately following RNA extraction, RT-
194	qPCR was performed using the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit and the
195	corresponding protocols provided by the manufacturer. The PKamp VariantDetect SARS-CoV-2
196	RT-PCR Assay kit combination C (which detects wildtype, Alpha, Beta and Gamma variants)
197	was used to identify variants present in these 210 pools. If combination D testing did not clearly
198	identify the variant present in a pool, that pool was then tested using combination F (which
199	detects Delta and Kappa variants).

200

# 201 **Results**:

202 Experiment 1 compared the three different human saliva pool processing methods, and the 203 results are shown in Figure 1. The RNase P gene was amplified from all pools using all three 204 processing methods. False positive results were obtained for the E gene in negative pools when 205 the Omni Direct-to-PCR method was used (Figure 1 and Figure 2). These samples were 206 determined to be false positives as they were initially tested following the established protocols by the University of Tennessee SARS-CoV-2 Surveillance Testing Laboratory and were known 207 to be negative for SARS-CoV-2. Of note is the observation that, in a small proportion of the 210 208 209 human saliva pools, the RdRP gene was not amplified with the assay that targets the ORF1ab

210	region (Figure 1). Amplification of the RdRP gene was only observed in pools processed when
211	the KingFisher extraction method was used.

212

213 <b>Figure 1</b> . qPCR assays	s targeting the E,	RdRP and RNase P	genes in 20 sample	pools plus
-----------------------------------	--------------------	------------------	--------------------	------------

controls. No amplification occurred in assays targeting the RdRP gene of the ORF1ab region of

the RdRP gene of SARS-CoV-2. The negative saliva pools are Pool 1 and Pool 2. Extraction

216 Negative Control (ENC); No Template Control (NTC); Synthetic SARS-CoV-2 RNA (PC).

217

**Figure 2.** Representative linear qPCR amplification plots for the E Gene showing false positive

amplification seen in SARS-CoV-2-negative samples with RNA extracted using the Omni

220 Direct-to-PCR method. The Omni Direct-to-PCR method using known negative saliva amplifies

with a Cq of 31.966, which is earlier than the known positive saliva with a Cq of 33.437. The

222 Positive sample example is Pool 4 and the negative sample is Pool 1.

223

224 Figure 2 illustrates representative linear RT-qPCR amplification plots showing the SARS-CoV-2 225 negative human saliva pool with the E gene amplifying earlier than in the SARS-CoV-2 positive 226 human saliva pool using the Omni RNA extraction method. Figure 2 demonstrates the false 227 positive amplification in the known SARS-CoV-2 negative human saliva using the Omni dPCR 228 method. Both the known SARS-CoV-2 positive human saliva pool and the known SARS-CoV-2 229 negative human saliva pool using the Omni dPCR method resulted in Cq value above 30. The 230 SalivaDirect extraction method and the Omni dPCR method both amplified higher than a Cq 231 value of 30 but the SalivaDirect extraction method did not show amplification in the known

- SARS-CoV-2 negative human saliva pool. Four independent replicate experiments usingdifferent reagents each time showed the same results.
- Experiment 2 tracked the variant distribution of SARS-CoV-2 that occurred during the spring
- semester of 2021 at the University of Tennessee, Knoxville campus. Table 3 outlines the various
- 236 deletions/mutations found in the variants of interest detected by PKamp VariantDirect SARS-
- 237 CoV-2 RT-PCR Assay kit with Table 4 showing the results of the variant tests for the pools used
- in this study. Figure 3 demonstrates how the SARS-CoV-2 variant prevalence changed over
- time. Early in the spring semester (mid-March), almost all positive pools were caused by the
- original wild type of the SARS-CoV-2 virus. Mid to late spring semester (mid-March to the end

of April), a shift in the SARS-CoV-2 variant was observed from wild type to mostly the Alpha

variant (UK strain). Of the 210 human saliva pools subjected to variant testing, only 18 pools

- failed to be identified with the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit
- combinations used in this study. The mutations of the SARS-CoV-2 variants found in the 18
- pools that failed to be identified with the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit
- combinations are listed in Table 4.

Variant	H69/V70 deletion	L242/L244 deletion	ORF1a 3675/3677 deletion	L452R	E484K	E484Q
Wild Type	-	-	-	-	-	-
Alpha	+	-	+	-	-	-
Beta	-	+	+	-	+	-
Gamma	-	-	+	-	+	-
Delta	-	-	-	+	-	-

**Table 3.** SARS-Cov-2 variants showing the deletions characteristic for each variant [reference?

where did this information come from?]. Presence of the mutation is indicated by (+) and

absence of the mutation is indicated by (-).

			ORF1a			
	H69/V70	L242/L244	3675/3677			
Sample	deletion	deletion	deletion	L452R	E484K	E484Q
Pool 21	+	-	-	-	-	-

Pool 22	+	-	?	-	-	-
Pool 23	+	-	?	-	-	-
Pool 24	+	-	?	-	-	-
Pool 25	+	-	?	-	-	-
Pool 26	?	+	-	-	-	-
Pool 27	+	-	-	-	-	-
Pool 28	-	-	?	-	-	-
Pool 29	+	-	-	-	-	-
Pool 30	+	-	-	-	-	-
Pool 31	+	-	?	-	-	-
Pool 32	?	-	-	-	-	-
Pool 33	+	-	?	-	-	-
Pool 34	+	-	?	-	-	-
Pool 35	+	-	?	-	-	-
Pool 36	+	-	?	-	-	-
Pool 37	+	-	?	-	-	-
Pool 38	+	-	?	-	-	-

Table 4. Mutations present in samples with unidentified variants after both combinations D and
 F of the PKamp VariantDetect SARS-CoV-2 RT-PCR assay kit tests were performed. Presence

253

**Figure 3.** SARS-CoV-2 variant distribution across the University of Tennessee campus in spring

255 2021. The asterisk (\*) depicts the week that spring break usually occurs.

256

# 257 **Discussion**:

As illustrated in Figure 2, we noted that the Omni Direct-to-PCR (dPCR) method resulted in

false positive amplification of the SARS-CoV-2 E gene in known SARS-CoV-2 negative human

saliva pools. Both the known SARS-CoV-2 positive pool and the known negative pool using

the Omni dPCR method showed amplification while the SalivaDirect extraction method did not

- show amplification in the known negative human saliva pool. A plausible explanation of the
- 263 observations is nonspecific amplification or artifacts in the known SARS-CoV-2 negative human
- saliva that cause the observed false positive results. These artifacts can be caused by an

of the mutation is indicated by (+) and absence of the mutation is indicated.

imbalance between primers, template and non-template RNA concentrations [14]. The negative 265 control for the Omni dPCR method showed no amplification, which leads us to attribute the 266 267 amplification of the E gene in the SARS-CoV-2 negative human saliva samples to the Omni dPCR method itself. The test was repeated 4 separate times with new reagents each time to 268 assure contamination was not the issue. Each repetition produced similar results. Contamination 269 270 of the kit was ruled out as a contributing factor from the manufacturer due to the quality control metrics reported wherein, they demonstrated the absence of any RNA in the kits via PCR and gel 271 272 visualization prior to shipment. 273 In Experiment 2, the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit identified which variant was present in the majority of human saliva pools collected on the University of 274 Tennessee, Knoxville campus during the spring of 2021. These results demonstrate the ability of 275 276 the variant detection kit to quickly detect and differentiate between SARS-CoV-2 variants. Although we cannot make definite conclusions on the variants present in these 18 SARS-CoV-2 277 positive human saliva pools listed in Table 4, we are able to gain some valuable information. The 278 279 majority of these 18 pools show H69/V70 deletions which is characteristic of the Alpha variant 280 lineage. The ORF1a 3675/3677 deletion, which was not detected or did not meet kit 281 specifications, may be in a region of the gene that has been speculated to have higher mutation 282 rates. Mutations found in the S-protein and the ORF1a and ORF1b genes can alter the viral 283 attachment, fusogenicity and/or immunogenicity as well as interrupt the viral proofreading [15, 284 16]. It has been suggested that some mutations in the ORF1a and ORF1b regions that alter the 285 viral replication can increase down-stream mutations [15, 16]. By piecing this information together, we can hypothesize that there may be a SARS-CoV-2 variant of the Alpha lineage, with 286 287 increased rates of mutation present in our sampling community. By monitoring the rate of these

mutations in the population, we can monitor the rate of transmission of this particular lineage andpotentially detect upcoming variants of interest.

290 It is interesting to note that there were no confirmed cases of the Delta variant on the University

- of Tennessee, Knoxville campus during the testing period. Considering the increased
- transmissibility, this variant was expected to be prevalent in the later months of the spring
- semester. Future studies could investigate the timeline of this variant in surrounding
- communities and allow a better understanding of the spread of the Delta variant on campus.
- 295

296 Before the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit combo F kit was available,

we attempted to identify variants using the GT Molecular RT-qPCR SARS-CoV-2 Delta Variant

298 Mutational Signature Assay Kit (Fort Collins, CO; SKU: 100172). We did not observe

amplification using this kit with any of the human saliva samples collected on campus.

300 Herein we successfully evaluated three qPCR-based assays for the detection of SARS-CoV-2

301 from saliva pooled samples obtained across the University of Tennessee, Knoxville campus in

arly 2021. While evaluating the three methods, the Omni Direct-to-PCR method, SalivaDirect,

and the King Fisher extraction method, they were shown to have a greater than 80% agreement

between all methods when identifying SARS-CoV-2 positive saliva pools. Secondary to the

305 successful identification of SARS-CoV-2 in the pooled saliva samples, it was shown that the

306 mechanical homogenization technique utilized by the Omni dPCR method provided sufficient

viral lysis and exposure of the viral RNA to go directly into qPCR detection, bypassing

- traditional extraction methods while maintaining sensitivity in comparison to two other
- 309 extraction-based methods evaluated. In addition to the evaluation of the three qPCR assays, the
- saliva pools were tested using the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay to track

the presence and proportionality of multiple variants of concern across the university's campus 311 312 during the spring 2021 semester. When evaluating variants, an observed shift from wild type to alpha variant was seen surrounding spring break. This shift corresponds with a national trend 313 seen at that time as the alpha variant transitioned to becoming the dominant variant across the 314 315 US. An unidentified variant was seen as the semester progressed, but it is likely that that is the 316 emergence of a recombination seen following spring break with large portions of the student body traveling and was an event that did not correspond with a variant of concern identified in 317 318 the utilized assay. Further evaluation of the unidentified variant could be considered for future 319 studies on the genomic diversity of SARS-CoV-2 across university populations. Overall, this manuscript successfully demonstrates the ability of multiple commercially available assays to 320 successfully utilize pooled saliva samples for highly sensitive SARS-CoV-2 detection. 321

#### 322

# 323 Acknowledgments

We acknowledge the University of Tennessee Office of Research and Engagement for providing funding for this project and Omni International Inc, A PerkinElmer Company. Additionally, we would like to acknowledge and thank Mr. Pete Tortorelli of Omni International for his continued leadership and financial support of our research endeavors.

### 328 Author Contributions

329 Author contributions to this manuscript have been determined utilizing the CRediT criteria as denoted below. MR Poindexter: conceptualization, data curation, formal analysis, investigation, 330 331 visualization, writing – original draft, writing – review and editing. **T Xu:** data curation, formal 332 analysis, methodology, investigation, visualization, writing - original draft, writing - review and 333 editing. CM Swift: data curation, formal analysis, visualization, writing – original draft, writing – review and editing. CM Proctor: investigation, methodology, writing – review and editing. F 334 Kara-Murdoch: formal analysis, validation, writing – review and editing. ZP Morehouse: 335 conceptualization, methodology, writing – original draft, writing – review and editing. GL Ryan: 336 337 methodology, writing - review and editing. FE Löffler: conceptualization, formal analysis, funding acquisition, investigation, methodology, project administration, resources, supervision, 338 writing – review and editing. **RJ Nash:** conceptualization, funding acquisition, investigation, 339 methodology, project administration, resources, supervision, writing – review and editing. 340

#### 341 Data Availability Statement

All data pertaining to this study is presented and available in the manuscript without alterations orrestrictions.

## 344 **Funding**

All funding for this project was provided from internal funding sources. The University of Tennessee Office of Research and Engagement provided internal funding to support the on campus research efforts while Omni International Inc, A PerkinElmer Company provided resources and internal funding to provide equipment and testing supplies to support this study.

## 349 **Conflicts of Interests**

350 Authors Caleb M Proctor, Gabriella L Ryan, and Rodney J Nash are all employed by Omni 351 International Inc, A PerkinElmer Company, which provided some funding and reagents for this work. Author Zachary P Morehouse has a contractor association with Omni International Inc, A 352 353 PerkinElmer Company. Authors Caleb M Proctor, Zachary P Morehouse, and Rodney J Nash are 354 all named inventors on the patented Omni dPCR method described in this paper, however, they 355 have no financial ownership of the method and do not have any financial incentives for its success or failure. The above authors attest that their relationship with Omni International Inc, A 356 357 PerkinElmer company has not influenced their work on this project, nor are they receiving any incentive for the publication of this work. Authors Magen R Poindexter, Tingting Xu, Cynthia M 358 Swift, Fadime Kara-Murdoch, and Frank E Löffler have no conflicts of interests to report. 359

360

# 361 **References:**

362	1.	Böger, B., et al., Systematic review with meta-analysis of the accuracy of diagnostic tests
363		for COVID-19. Am J Infect Control, 2021. 49(1): p. 21-29.
364	2.	Zapor, M., Persistent Detection and Infectious Potential of SARS-CoV-2 Virus in Clinical
365		Specimens from COVID-19 Patients. Viruses, 2020. 12(12).
366	3.	Hirotsu, Y., H. Mochizuki, and M. Omata, Double-quencher probes improve detection
367		sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a
368		reverse-transcription polymerase chain reaction (RT-PCR) assay. Journal of virological
369		methods, 2020. <b>284</b> : p. 113926-113926.

370	4.	Corman, V.M., et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-
371		<i>PCR</i> . Euro surveillance : bulletin Europeen sur les maladies transmissibles = European
372		communicable disease bulletin, 2020. $25(3)$ : p. 2000045.
373	5.	Ash, K.T., et al., Coding-Complete Genome Sequence of a SARS-CoV-2 Variant
374		Obtained from Raw Sewage at the University of Tennessee-Knoxville Campus.
375		Microbiology Resource Announcements, 2021. 10(47).
376	6.	Kuchinski, K.S., A.N. Jassem, and N.A. Prystajecky, Assessing oligonucleotide designs
377		from early lab developed PCR diagnostic tests for SARS-CoV-2 using the PCR_strainer
378		<i>pipeline</i> . Journal of clinical virology : the official publication of the Pan American
379		Society for Clinical Virology, 2020. <b>131</b> : p. 104581-104581.
380	7.	Chakraborty, C., et al., Evolution, Mode of Transmission, and Mutational Landscape of
381		Newly Emerging SARS-CoV-2 Variants. mBio, 2021. 12(4): p. e0114021.
382	8.	Chakraborty, D., A. Agrawal, and S. Maiti, Rapid identification and tracking of SARS-
383		CoV-2 variants of concern. The Lancet, 2021. 397(10282): p. 1346-1347.
384	9.	Ransom, E.M., et al., Comparison of Extraction Methods and Thermocyclers for SARS-
385		CoV-2 Molecular Detection Using Clinical Specimens. Journal of Clinical Microbiology,
386		2020. <b>58</b> (10): p. e01622-20.
387	10.	Rodríguez Flores, S.N., et al., Comparison Between a Standard and SalivaDirect RNA
388		Extraction Protocol for Molecular Diagnosis of SARS-CoV-2 Using Nasopharyngeal
389		Swab and Saliva Clinical Samples. Frontiers in Bioengineering and Biotechnology, 2021.
390		9.
391	11.	Morehouse, Z.P., et al., Validation of a direct-to-PCR COVID-19 detection protocol
392		utilizing mechanical homogenization: A model for reducing resources needed for
393		accurate testing. PLOS ONE, 2021. 16(8): p. e0256316.
394	12.	Vogels, C.B.F., et al., SalivaDirect: A simplified and flexible platform to enhance SARS-
395		<i>CoV-2 testing capacity.</i> Med (N Y), 2021. <b>2</b> (3): p. 263-280.e6.
396	13.	Schoch, C.L., et al., NCBI Taxonomy: a comprehensive update on curation, resources
397		and tools. Database (Oxford), 2020. 2020.
398	14.	Ruiz-Villalba, A., et al., Amplification of nonspecific products in quantitative polymerase
399		chain reactions (qPCR). Biomolecular detection and quantification, 2017. 14: p. 7-18.
400	15.	Pachetti, M., et al., Emerging SARS-CoV-2 mutation hot spots include a novel RNA-
401		dependent-RNA polymerase variant. Journal of Translational Medicine, 2020. 18(1): p.
402		179.
403	16.	Ilmjärv, S., et al., Concurrent mutations in RNA-dependent RNA polymerase and spike
404		protein emerged as the epidemiologically most successful SARS-CoV-2 variant. Scientific
405		Reports, 2021. <b>11</b> (1): p. 13705.





Figure 1







Variant Distribution Over Time

Week of Sample Collection

Figure 3